In fending off Valeant's cash and stock bid, Allergan repeatedly questioned the financial strength of its unwanted suitor. In the end, it agreed to a $66 billion buyout by generics maker Actavis Plc. Valeant said last month it …
Valeant Is Stepping Out Of The Growth-By-Acquisitions Game
Next post: Larry Summers Financial Times Op-Ed – Business Insider
Previous post: Healthy Main Dishes: Greek Chicken Pasta